[go: up one dir, main page]

DE60042326D1 - Radiomarkierungssatz und bindungstest - Google Patents

Radiomarkierungssatz und bindungstest

Info

Publication number
DE60042326D1
DE60042326D1 DE60042326T DE60042326T DE60042326D1 DE 60042326 D1 DE60042326 D1 DE 60042326D1 DE 60042326 T DE60042326 T DE 60042326T DE 60042326 T DE60042326 T DE 60042326T DE 60042326 D1 DE60042326 D1 DE 60042326D1
Authority
DE
Germany
Prior art keywords
radiolabeling
kit
radiomarking
binding test
kits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042326T
Other languages
English (en)
Inventor
Paul Chinn
Ronald Morena
Michael Labarre
John E Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE60042326D1 publication Critical patent/DE60042326D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Packages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60042326T 1999-03-01 2000-02-29 Radiomarkierungssatz und bindungstest Expired - Lifetime DE60042326D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay

Publications (1)

Publication Number Publication Date
DE60042326D1 true DE60042326D1 (de) 2009-07-16

Family

ID=22984524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042326T Expired - Lifetime DE60042326D1 (de) 1999-03-01 2000-02-29 Radiomarkierungssatz und bindungstest

Country Status (35)

Country Link
US (2) US20020102208A1 (de)
EP (2) EP1192463B1 (de)
JP (1) JP4704570B2 (de)
KR (1) KR100729247B1 (de)
CN (1) CN1235639C (de)
AT (1) ATE433108T1 (de)
AU (1) AU776747B2 (de)
BG (1) BG65690B1 (de)
BR (2) BRPI0017596B8 (de)
CA (2) CA2742153C (de)
CY (2) CY1109335T1 (de)
CZ (2) CZ306959B6 (de)
DE (1) DE60042326D1 (de)
DK (2) DK1192463T3 (de)
EE (1) EE05650B1 (de)
ES (2) ES2328100T3 (de)
HK (1) HK1045730B (de)
HR (1) HRP20010714B1 (de)
HU (2) HU229627B1 (de)
IL (1) IL145109A0 (de)
ME (1) ME00782B (de)
MX (1) MXPA01008837A (de)
MY (1) MY138674A (de)
NO (2) NO329142B1 (de)
NZ (2) NZ513788A (de)
PL (1) PL205780B1 (de)
PT (2) PT2112512E (de)
RS (1) RS51778B (de)
RU (1) RU2251110C2 (de)
SI (2) SI2112512T1 (de)
SK (2) SK287745B6 (de)
TW (1) TWI294969B (de)
UA (1) UA78484C2 (de)
WO (1) WO2000052473A2 (de)
ZA (1) ZA200106943B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (de) 1999-08-11 2008-05-07 Biogen Idec Inc. Neue klinische Parameter zur Bestimmung der hämatologischen Toxizität vor einer Strahlenimmuntherapie
EP1326896B1 (de) 2000-10-02 2010-11-24 Novartis Vaccines and Diagnostics, Inc. Humane antikörper gegen cd40
AU2002307037B2 (en) * 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7591953B2 (en) * 2003-06-25 2009-09-22 Peregrine Pharmaceuticals, Inc. Methods and apparatus for continuous large-scale radiolabeling of proteins
EP1684869B1 (de) 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von b-zell-bedingtem krebs
EP1682178B8 (de) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von krebs mit expression des cd40-antigens
CA2544364A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
EP2301575A1 (de) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Verfahren zur Therapie von soliden Tumoren mit CD40-Zelloberflächenantigenexpression
EP2312315A1 (de) 2005-05-18 2011-04-20 Novartis AG Verfahren zur Diagnose und Behandlung von Krankheiten mit einer autoimmunen und/oder entzündlichen Komponente
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
CN101247755B (zh) * 2005-08-25 2018-04-24 皇家飞利浦电子股份有限公司 用于针对性医疗的基于图像的设备
ES2548518T3 (es) 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Conjugado molecular
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
ES2618352T3 (es) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20100130449A1 (en) * 2006-11-10 2010-05-27 Alphaptose Gmbh Use of Tri-Substituted Glycerol Compounds for the Treatment of Radiation Injuries
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
NO2740744T3 (de) 2007-01-09 2018-08-25
CN101896163A (zh) * 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 抗体制剂
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US8603480B2 (en) 2008-07-16 2013-12-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
KR101407216B1 (ko) 2008-07-16 2014-06-16 인스티튜트 포 리서치 인 바이오메드슨 인간 사이토메갈바이러스 중화 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
ES2662519T3 (es) 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
AU2009305113B2 (en) 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
DK3117709T3 (en) 2010-03-12 2018-11-26 Genzyme Corp COMBINATION THERAPY FOR TREATMENT OF BREAST CANCER
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
AR082680A1 (es) * 2010-08-13 2012-12-26 Jose Raimundo Filho Metodo y composicion para producir azucar clarificada
PL2683360T3 (pl) 2011-03-11 2016-09-30 Pegylowana apelina i jej zastosowania
US9587010B2 (en) 2011-07-18 2017-03-07 The Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
US9498531B2 (en) 2012-03-20 2016-11-22 Humabs Biomed Sa Antibodies that neutralize RSV, MPV and PVM and uses thereof
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EP3564259A3 (de) 2012-11-09 2020-02-12 Innate Pharma Kennungen für tgase-vermittelte konjugation
WO2014164503A1 (en) 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
EP3733244A1 (de) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon
US9835626B2 (en) 2014-02-27 2017-12-05 Board Of Regents, The University Of Texas System Methods and compositions for isolating exosomes
CN116333148A (zh) 2014-03-19 2023-06-27 建新公司 靶向模块的位点特异性糖工程化
KR102553870B1 (ko) 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
CN113173990B (zh) 2014-07-15 2024-10-29 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016014613A1 (en) 2014-07-22 2016-01-28 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
AU2015330869B2 (en) 2014-10-09 2021-07-08 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR122020023406B1 (pt) 2014-11-18 2023-10-31 Institut Pasteur Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
ES2894777T3 (es) 2015-06-01 2022-02-15 Medimmune Llc Neutralización de moléculas de unión anti-influenza y usos de las mismas
CA2993972A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
WO2017040708A1 (en) 2015-08-31 2017-03-09 Fruition Marketing, Llc Consumer usable device with redeemable member
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
US11421026B2 (en) 2015-09-30 2022-08-23 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
KR20250130692A (ko) 2016-01-13 2025-09-02 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
WO2018010789A1 (en) * 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
EP3618865A4 (de) 2017-05-05 2021-05-05 Vaccinex, Inc. Menschlicher anti-semaphorin-4d-antikörper
ES2991605T3 (es) 2017-07-19 2024-12-04 Hoffman Tech Llc Composiciones para el tratamiento de los trastornos relacionados con el estrés
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
CN118108836A (zh) 2018-12-19 2024-05-31 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
AU2020336980B2 (en) 2019-08-29 2025-07-10 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis B virus infection
KR20220148235A (ko) 2020-02-28 2022-11-04 젠자임 코포레이션 최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
IL298814A (en) 2020-06-11 2023-02-01 Vaccinex Inc Use of cxcl13 binding molecules to promote peripheral nerve regeneration
WO2022164805A1 (en) 2021-01-26 2022-08-04 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
EP4608859A1 (de) 2022-10-25 2025-09-03 Ablynx N.V. Glycoengineering-fc-varianten-polypeptide mit verbesserter effektorfunktion
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025177185A1 (en) * 2024-02-20 2025-08-28 Janssen Biotech, Inc. Materials and methods for biologic affinity analysis
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
WO2026024319A1 (en) 2024-07-23 2026-01-29 Bird Rock Bio Sub, Inc. Treatment of obesity and obstructive sleep apnea

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井　三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
DK172629B1 (da) * 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0529645B1 (de) * 1986-09-05 1996-10-23 GANSOW, Otto A. Verfahren zur Herstellung hauptkettenpolysubstituierter Chelate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1992011864A1 (en) * 1991-01-11 1992-07-23 Cryopharm Corporation Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
WO1989011475A1 (en) * 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0556285A4 (en) 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
EP0752248B1 (de) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) * 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Also Published As

Publication number Publication date
NO20014245L (no) 2001-10-31
SI2112512T1 (sl) 2015-02-27
DK1192463T3 (da) 2009-10-05
BG65690B1 (bg) 2009-06-30
ATE433108T1 (de) 2009-06-15
CA2362119C (en) 2012-12-11
SK287745B6 (sk) 2011-08-04
HUP0202522A3 (en) 2011-03-28
TWI294969B (de) 2008-03-21
PT2112512E (pt) 2015-01-13
SI1192463T1 (sl) 2009-10-31
BRPI0017596B8 (pt) 2023-04-25
ES2328100T3 (es) 2009-11-10
MY138674A (en) 2009-07-31
PL205780B1 (pl) 2010-05-31
BRPI0008719B1 (pt) 2015-07-21
DK2112512T3 (en) 2014-12-15
ME00782B (me) 2012-03-20
BRPI0017596B1 (pt) 2015-09-01
CN1235639C (zh) 2006-01-11
EP2112512B1 (de) 2014-11-19
CZ20013126A3 (cs) 2002-07-17
WO2000052473A2 (en) 2000-09-08
BRPI0017596A2 (pt) 2011-09-27
NO20100717L (no) 2001-10-31
NZ530868A (en) 2005-12-23
US7608241B2 (en) 2009-10-27
KR100729247B1 (ko) 2007-06-15
MXPA01008837A (es) 2002-05-14
WO2000052473A3 (en) 2002-01-31
HK1045730A1 (en) 2002-12-06
JP2002538179A (ja) 2002-11-12
KR20020021772A (ko) 2002-03-22
JP4704570B2 (ja) 2011-06-15
NO330705B1 (no) 2011-06-20
HUP1300275A2 (en) 2002-11-28
SK288096B6 (sk) 2013-07-02
CA2362119A1 (en) 2000-09-08
AU3505200A (en) 2000-09-21
SK12162001A3 (sk) 2002-12-03
RU2251110C2 (ru) 2005-04-27
EP1192463A2 (de) 2002-04-03
WO2000052473A9 (en) 2001-03-08
IL145109A0 (en) 2002-06-30
US20020102208A1 (en) 2002-08-01
PT1192463E (pt) 2009-09-10
AU776747B2 (en) 2004-09-23
EE200100465A (et) 2002-10-15
ES2526723T3 (es) 2015-01-14
RS51778B (sr) 2011-12-31
HRP20010714A2 (en) 2003-02-28
HK1045730B (zh) 2006-08-18
NO329142B1 (no) 2010-08-30
HK1131208A1 (en) 2010-01-15
CN1345417A (zh) 2002-04-17
EP1192463B1 (de) 2009-06-03
HRP20010714B1 (hr) 2009-01-31
CA2742153A1 (en) 2000-09-08
NZ513788A (en) 2004-03-26
CZ303262B6 (cs) 2012-07-04
CY1109335T1 (el) 2014-07-02
UA78484C2 (en) 2007-04-10
EE05650B1 (et) 2013-04-15
YU61601A (sh) 2004-07-15
US20050169838A1 (en) 2005-08-04
PL352531A1 (en) 2003-08-25
NO20014245D0 (no) 2001-08-31
EP2112512A2 (de) 2009-10-28
CY1116265T1 (el) 2017-02-08
HU230516B1 (hu) 2016-10-28
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
HU229627B1 (en) 2014-03-28
ZA200106943B (en) 2002-11-22
EP2112512A3 (de) 2009-12-16
CZ306959B6 (cs) 2017-10-11
HUP0202522A2 (hu) 2002-11-28
BRPI0008719A (pt) 2001-12-26
CA2742153C (en) 2015-04-14

Similar Documents

Publication Publication Date Title
DE60042326D1 (de) Radiomarkierungssatz und bindungstest
IL182500A0 (en) Cop1 molecules and uses thereof
EA202092087A1 (ru) Анализы для выявления нейродегенеративных заболеваний
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
NO20005694L (no) Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutiske fremgangsmåter for behandling av angiogenese
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
ATE423220T1 (de) Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
ATE482396T1 (de) Blockierter enzymsondenkomplex
ATE432364T1 (de) Sonden zum nachweis von tumorzellen
ATE309539T1 (de) Verfahren zum bestimmen humaner thymidylatsynthase und versuchskit
ATE308555T1 (de) Tumorsuppressormoleküle und nutzungsverfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition